EP4204049A1 - Inhalateur et procédé et agencement d'administration d'un principe actif - Google Patents

Inhalateur et procédé et agencement d'administration d'un principe actif

Info

Publication number
EP4204049A1
EP4204049A1 EP21769926.3A EP21769926A EP4204049A1 EP 4204049 A1 EP4204049 A1 EP 4204049A1 EP 21769926 A EP21769926 A EP 21769926A EP 4204049 A1 EP4204049 A1 EP 4204049A1
Authority
EP
European Patent Office
Prior art keywords
data
active substance
inhaler
administration
air
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21769926.3A
Other languages
German (de)
English (en)
Inventor
Christian HANNEKEN
Michael Joseph CAPONE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koerber Technologies GmbH
Original Assignee
Koerber Technologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koerber Technologies GmbH filed Critical Koerber Technologies GmbH
Publication of EP4204049A1 publication Critical patent/EP4204049A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A61M15/0066—Inhalators with dosage or measuring devices with means for varying the dose size
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A24F40/50—Control or monitoring
    • A24F40/53—Monitoring, e.g. fault detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
    • A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
    • A61M11/045—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters using another liquid as heat exchanger, e.g. bain-marie
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0085—Inhalators using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A24F40/05—Devices without heating means
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A24F40/10—Devices using liquid inhalable precursors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
    • A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
    • A61M11/042—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters electrical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A61M2016/0015—Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors
    • A61M2016/0018—Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors electrical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A61M2016/0027—Accessories therefor, e.g. sensors, vibrators, negative pressure pressure meter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A61M2016/003—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
    • A61M2016/0033—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter electrical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/27—General characteristics of the apparatus preventing use
    • A61M2205/276—General characteristics of the apparatus preventing use preventing unwanted use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/33—Controlling, regulating or measuring
    • A61M2205/332—Force measuring means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/33—Controlling, regulating or measuring
    • A61M2205/3331—Pressure; Flow
    • A61M2205/3334—Measuring or controlling the flow rate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/33—Controlling, regulating or measuring
    • A61M2205/3331—Pressure; Flow
    • A61M2205/3358—Measuring barometric pressure, e.g. for compensation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/33—Controlling, regulating or measuring
    • A61M2205/3379—Masses, volumes, levels of fluids in reservoirs, flow rates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/35—Communication
    • A61M2205/3546—Range
    • A61M2205/3553—Range remote, e.g. between patient's home and doctor's office
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/35—Communication
    • A61M2205/3546—Range
    • A61M2205/3561—Range local, e.g. within room or hospital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/35—Communication
    • A61M2205/3546—Range
    • A61M2205/3569—Range sublocal, e.g. between console and disposable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/35—Communication
    • A61M2205/3576—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver
    • A61M2205/3584—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver using modem, internet or bluetooth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/35—Communication
    • A61M2205/3576—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver
    • A61M2205/3592—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver using telemetric means, e.g. radio or optical transmission
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/50—General characteristics of the apparatus with microprocessors or computers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/82—Internal energy supply devices
    • A61M2205/8206—Internal energy supply devices battery-operated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/04—Heartbeat characteristics, e.g. ECG, blood pressure modulation
    • A61M2230/06—Heartbeat rate only
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/20—Blood composition characteristics
    • A61M2230/201—Glucose concentration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/30—Blood pressure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01F—MEASURING VOLUME, VOLUME FLOW, MASS FLOW OR LIQUID LEVEL; METERING BY VOLUME
    • G01F1/00—Measuring the volume flow or mass flow of fluid or fluent solid material wherein the fluid passes through a meter in a continuous flow
    • G01F1/05—Measuring the volume flow or mass flow of fluid or fluent solid material wherein the fluid passes through a meter in a continuous flow by using mechanical effects
    • G01F1/34—Measuring the volume flow or mass flow of fluid or fluent solid material wherein the fluid passes through a meter in a continuous flow by using mechanical effects by measuring pressure or differential pressure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01F—MEASURING VOLUME, VOLUME FLOW, MASS FLOW OR LIQUID LEVEL; METERING BY VOLUME
    • G01F1/00—Measuring the volume flow or mass flow of fluid or fluent solid material wherein the fluid passes through a meter in a continuous flow
    • G01F1/68—Measuring the volume flow or mass flow of fluid or fluent solid material wherein the fluid passes through a meter in a continuous flow by using thermal effects
    • G01F1/684—Structural arrangements; Mounting of elements, e.g. in relation to fluid flow
    • G01F1/688—Structural arrangements; Mounting of elements, e.g. in relation to fluid flow using a particular type of heating, cooling or sensing element
    • G01F1/69—Structural arrangements; Mounting of elements, e.g. in relation to fluid flow using a particular type of heating, cooling or sensing element of resistive type
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01F—MEASURING VOLUME, VOLUME FLOW, MASS FLOW OR LIQUID LEVEL; METERING BY VOLUME
    • G01F1/00—Measuring the volume flow or mass flow of fluid or fluent solid material wherein the fluid passes through a meter in a continuous flow
    • G01F1/76—Devices for measuring mass flow of a fluid or a fluent solid material
    • G01F1/86—Indirect mass flowmeters, e.g. measuring volume flow and density, temperature or pressure
    • G01F1/88—Indirect mass flowmeters, e.g. measuring volume flow and density, temperature or pressure with differential-pressure measurement to determine the volume flow

Definitions

  • the invention relates to an inhaler, comprising a housing with a base body, the base body being designed and set up to accommodate an active substance container containing an active substance, an air duct extending between at least one air inlet opening and an inhalation opening within the housing, an administration element for nebulizing or vaporizing the active substance fed from the active substance container to the administration element for admixture to the air flowing in the air duct, an electronic control device, an electronic data memory, and a sensor system with a flow measuring device for measuring the volume and/or mass flow of the air flowing through the air duct and/or the active substance flowing through the air duct for storage as active substance delivery data in the electronic data storage device.
  • the invention relates to a method for administering an active ingredient with an inhaler.
  • the invention also relates to an arrangement designed and set up for administering an active substance, comprising an inhaler and a communication terminal comprising a mobile application and/or an application terminal and/or a cloud storage device.
  • ENDS Electronic Nicotine Delivery System
  • a person When consuming stimulants or administering active ingredients, a person usually sucks on a mouthpiece of the inhaler, which creates a suction pressure in an air duct with an air inlet opening and in the area of the mouthpiece with an air outlet side, which generates an air flow through the air duct.
  • the mouthpiece includes an ingestion opening through which the user induces ingestion of the active substance.
  • the air flow can also be done mechanically, e.g. B. be generated by a pump.
  • the active substance is usually delivered to the airway by a delivery element.
  • the administration element is synonymous with all components that provide a solid and/or liquid active ingredient as an inhalable substance.
  • the administering element can be an evaporator unit, for example.
  • the evaporator unit can e.g. B.
  • the evaporator unit can also have a laser light source or the like as an evaporating element.
  • devices for generating mechanical driving forces, compressors or the like for generating inhalable substances also come under the term of the administration element or the evaporator unit.
  • Individual components of the inhaler namely z. B. a body, a drug container and a delivery element can be in a common component, z. B. an evaporator cartridge, be summarized.
  • the inhaler or individual components thereof can be designed as a disposable item which is designed for a finite number of inhalation puffs by a consuming person or a user.
  • the inhaler can also be designed as a reusable item, in which case the components must be adapted to the different uses of the inhaler.
  • Individual components such as the drug container are regularly designed as disposable items.
  • An electronic control device and an energy source are known for operating and controlling an inhaler.
  • the energy source can e.g. B. a disposable electrochemical battery or a rechargeable electrochemical battery, z. B. be a Li-ion battery, by means of which the administration element, the electronic control device, the electronic data memory or other consumers are supplied with energy via electrical contacts.
  • the electronic and/or electrical control device serves to control the electrical and/or electronic data processing processes that occur in connection with the inhaler.
  • an inhaler is an oral way of administering medicaments and thus therapeutically or pharmacologically active drug compositions to a patient. If inhalers are used as part of a therapeutic approach are administered, a doctor or other person authorized to provide therapy prescribes a treatment consisting of a drug and regimen.
  • medicament and active substance are to be understood synonymously, since the medicament contains the active substance.
  • Medicaments to be administered by inhalers comprise the desired active ingredient stored in a container, such as a canister, and administered by means of the inhaler for inhalation.
  • Inhalers usually have a spray valve that releases a fixed amount of the active substance with each spray. The manufacturer selects the inhaler that releases the desired dose per puff.
  • the canister is usually a disposable product.
  • the main body of the inhaler is regularly designed for repeated use.
  • the active substance to be administered by the inhaler is usually present in an inhalation medium.
  • the inhalation medium with the active ingredient is usually stored in an active ingredient container.
  • the inhalation medium is stored on or in the inhaler. Different mixtures with different components of the same or different vapor densities are used as the inhalation medium.
  • the mixture can have corresponding pharmacological components and active ingredients and combinations of active ingredients.
  • an inhalation medium for medical use comprises a solvent in which the active substance is dissolved.
  • a typical mixture for use in an e-cigarette has e.g. B. components of glycerol and propylene glycol, possibly enriched with nicotine and / or almost any flavorings.
  • active substance is understood to mean all substances that can be inhaled for pleasure and/or for therapeutic purposes.
  • a regimen describes specified application periods and the course of taking or administering a drug. Regimes are also sometimes referred to as exercise, plan, therapy plan, etc.
  • the physician In determining the regimen, the physician must consider various factors such as the patient's age, weight, comorbidities, and/or medications already prescribed. It is not possible for the doctor treating you to check the dose of the active substance actually taken, since the doctor is usually unable to check the intake, which is why the amount of an active substance actually consumed deviates from the planned amount can. If there are indications that the patient is undertaking the drug, the doctor can increase the dose by modulating the regimen, for example adding more periods and/or increasing the repetitions in which the drug is to be taken via the inhaler. The regimen thus specifies the dose and frequency at which the medication is to be taken in order to achieve the best possible effect.
  • the controller activates the administering element, for example as a result of a negative pressure measured by a sensor during an inhalation puff.
  • the amount of active substance released is essentially determined by the activation duration of the administration element and cannot be changed.
  • conventional inhalers cannot monitor or record the time and duration of use.
  • the inhalers can be used at any time of the day without restrictions, with the dose being freely and uncontrollably modifiable by the patient.
  • the doctor can only evaluate through further checks whether the regimen was effective and make adjustments if necessary.
  • a check and/or monitoring of whether the medication was administered according to the proposed regimen is not possible with the current inhalers.
  • many factors can lead to the regime not being followed. The patient may not understand or forget the application period and decrease the frequency by mistake or abuse, or increase it intentionally. This can lead, for example, to patients taking excessive amounts of the active substance, their prescriptions running out prematurely, which means that their complaints are not treated.
  • a conventional inhaler cannot adapt the amount of active substance released to the patient. As soon as the inhaler is activated, the entire dose is usually released. This leads to the patient having to take a deep breath in at the same time in order to inhale the entire amount of active ingredient provided by the inhaler.
  • the lung function of patients is different, or can vary greatly during a day. For example, high humidity or exertion can greatly reduce the patient's receptivity.
  • the uninhaled amount will remain in the airway or mouthpiece, in the chamber of the inhaler or in the patient's oral cavity. In any case, complete absorption of the released active substance cannot be guaranteed. If inhaled incorrectly, some active ingredients can cause fungal growth in the oral cavity. Information on this is regularly included in the instructions for use of the inhalers, according to which it is recommended to rinse your mouth after inhaling. In the event of incorrect inhalation processes, however, the amount of active substance taken up by the patient is less than the amount of active substance prescribed by the doctor and the success of the treatment can be reduced.
  • a conventional inhaler has no feedback to monitor the operation performed or the intake of the active ingredient performed.
  • the patient and the treating physician have no way of ensuring that an inhaler is being used consistently according to the prescribed directions.
  • the patient is not provided with any tools to safely use the inhaler or take the medication.
  • the doctor can therefore not establish a causal connection between not taking the drug and the success of the therapy. Without knowing that the patient has repeatedly forgotten to take the medication, the doctor will take further measures to achieve the desired therapeutic success. Examples of such measures are increasing the dosage of the drug or increasing the frequency of taking the drug, or using a different drug.
  • the container or canister is not functionally coupled to and is not tied to the delivery element of the inhaler.
  • the patient can use a wide variety of containers for his inhaler contact, which administer, for example, a larger amount of the active ingredient per spray and / or have different concentrations of active ingredient than the manufacturer or the doctor intended or prescribed.
  • the object of the present invention is the monitoring of the use of an inhaler and the dynamic adjustment of the administration of an active substance for the safe and controllable administration of medicaments or an inhalation medium with an active substance to a patient or user, and thus an improved effectiveness of treatments.
  • an inhaler of the type mentioned at the outset in that the electronic control device is designed and set up to convert active substance administration data provided in the electronic data memory for administration of the active substance through the inhaler into administration data in order to control the admixture of the active substance through the administration element To control air channel flowing air, and wherein the electronic control device is set up to calculate the active substance released from the active substance container based on the active substance release data recorded by means of the flow measuring device and to compare it with the active substance administration data.
  • the design of the inhaler it is possible to precisely record the active ingredient actually ingested by the user. In this way, it can be reliably detected whether the amount of active ingredient released by the administering element matches the amount that has flowed through the air duct.
  • the design of the inhaler is therefore used in particular to record specific data that allow conclusions to be drawn about the quality of the inhalation process.
  • the inventive design of the electronic control device for controlling the admixture of the active substance by means of the administering element to the air flowing in the air duct which is carried out in particular by the user sucking on the air duct, provides a simple way of measuring the amount of the substance in the air duct in further inhalation processes to vary the drug to be delivered.
  • the drug administration data is also known as exercise, therapy plan, therapy regimen, etc. in the medical context.
  • the drug administration dates are usually determined by the person authorized to dispose of the drug (e.g. the doctor) and/or by the provider of the drug, ie the drug administration dates can be provided directly with the inhaler or the drug container. Ideally, the user of the inhaler should not be able to make any manual changes to the active substance administration data. If the active substance administration data is generated by the person authorized to dispose of it (doctor), he or she can use technical aids (machine processing).
  • the regime primarily influences the treatment and determines the dose, which is determined by the active ingredient used, among other things.
  • the inhaler converts the drug delivery data into the delivery data, which preferably can be adjusted dynamically, but always follows the overall prescription of the drug delivery data.
  • the administration dates may differ from the drug administration dates, however, the parameters of the total dose and the drug remain the same. For example, when determining drug administration dates, the physician must consider various factors such as the patient's age, weight, comorbidities, and/or medications already prescribed.
  • a conversion of the active ingredient administration data into administration data by means of the electronic control device enables reliable operation of the inhaler. Due to the large number of electronic components in the inhaler, there is no provision for manual operation of the inhaler, in particular of the administering element.
  • the active ingredient administration data include the desired amount of active ingredient that is to be delivered to the user with the inhaler, for example during an inhalation process.
  • the electronic control device converts the drug delivery data into machine-readable information, by means of which the delivery element controls the admixture of the drug into the air passage.
  • the administration data are preferably also stored in the electronic data memory.
  • the administering element is activated in particular by means of the electronic control device.
  • One possibility for controlling the administering element preferably includes controlling the negative pressure measured by a sensor during an inhalation puff.
  • the amount of active substance released is essentially determined by the activation period of the administration element set.
  • an administration element can be a heating element, an ultrasonic nebulizer, which vaporizes or nebulizes liquid with the aid of a piezo element, a gas compressor, which builds up gas pressure and thereby nebulizes or vaporizes liquid through a nozzle, or a nebulization membrane, in which high-frequency vibration of the membrane liquid is vaporized or nebulized.
  • the electronic control device is, for example, a microcontroller or a microprocessor.
  • such electronic control devices are generally used to carry out computing processes of any kind. Due to the more compact design and architecture of these components, it is possible for the control devices to be used in small electronic devices.
  • the electronic control device is preferably designed and set up to use the drug data to calculate the administration data for dispensing the active ingredient as a function of the air volume during a patient's breath on the inhaler, and on the other hand, a large number of other calculation and work processes are possible using the electronic control device , In particular, there is a use for the operation and analysis of the inhaler.
  • the electronic control device is further preferably designed and set up to operate the inhaler with the operating data in order to ensure the basic functionality.
  • the electronic control device preferably monitors the delivery quantity or the active substance composition during a breath by means of suitable sensors.
  • the electronic control device uses suitable sensors to monitor the volume of air inhaled through the inhaler during a puff, as a result of which specific quantities of the active substance released can be calculated.
  • the electronic control device advantageously includes software or a program for operating the electronic control device, in particular for controlling the inhaler and for editing and processing data.
  • the active substance release data recorded by the sensor system of the flow rate measuring device can be determined, as a result of which specific conclusions can be drawn about the active substance quantities administered by comparing them with the active substance administration data.
  • the comparison of the data is conceivable, for example, in relative numbers of drug release data and drug administration data.
  • the comparison should also include the recording of absolute numbers of Active substance administration data and active substance release data include, ie a recording of the individual values in order to compare them with one another, if necessary, only afterwards.
  • the active ingredient release data is recorded over part or all of the duration of an inhalation process.
  • a comparison then takes place of the active substance release data recorded by means of the flow measuring device with the active substance release data stored in the data memory.
  • a comparison is made between the specified puff profile and measured values that are recorded during a specific inhalation puff.
  • the invention creates data on the basis of the measured air flow, i.e. the air flowing in the air duct and/or the active substance flowing through the air duct, the air flowing in the air duct usually comprising or absorbing the flowing active substance.
  • the amount of active ingredient released during the inhalation process is preferably recorded during an inhalation process, from which the active ingredient release data are determined. Due to the preferred acquisition of data between the air flow during an inhalation process, and preferably also the amount of active substance released during the inhalation process, there is a comprehensible data situation on the actual active substance release data.
  • the sensor system with the flow rate measuring device can advantageously be a differential pressure measuring device, which enables the air volume flow (or air mass flow) to be reliably measured using simple means in a mobile inhaler.
  • the differential pressure measuring device comprises a first pressure sensor, which is arranged to measure the ambient air pressure of the inhaler, and a second pressure sensor, which is arranged to measure the air pressure in the air duct of the inhaler.
  • the flow rate measuring device can advantageously be a hot wire measuring device (thermal anemometer). At least one wire element arranged in the air duct of the inhaler is electrically heated. The flow around the wire element causes heat to be transported into the flowing air, i.e. the wire element is cooled. By measuring the temperature-dependent electrical resistance, the flow rate and thus the volume flow of the air flowing through the air duct can be determined.
  • a hot wire measuring device thermo anemometer
  • the flow rate measuring device can also be used to determine the air volume flow over time. This advantageously results in a “puff profile” or measured puff profile of the entire puff or inhalation process.
  • the sensor system preferably has a liquid quantity sensor for detecting the quantity of liquid released by a vaporization device during an inhalation puff. This allows a more precise adjustment of the amount of liquid to be evaporated to the user's respective draw profile.
  • the liquid quantity sensor is an air humidity sensor.
  • the air humidity sensor preferably comprises two humidity measuring elements which are arranged in the air duct of the inhaler to measure the air humidity.
  • the first humidity measuring element is arranged in the area of the air inlet or in the air duct upstream of the administering element and measures a reference value of the air humidity before liquid vapor is added.
  • the second humidity measuring element is arranged in the air duct downstream of the administering element, for example in the area of the mouthpiece, and measures the humidity directly before the air-aerosol-vapour mixture is inhaled by the user.
  • the inhaler comprises at least one energy source, whereby the at least one energy source can be used to generate the inhalable active substance, for example for a nebulization or heating element, and is provided for the energy supply of the other electrical and electronic components of the inhaler.
  • the inhaler preferably comprises a communication device designed and set up for sending and/or receiving data.
  • the communication device represents a device for data transmission in order to exchange data with the inhaler, or to send and/or receive it; in other words, an exchange of data is possible by means of the communication device. It is thus possible by means of the communication device for the inhaler to establish a connection with other communication devices in order to send data with them and/or to receive data from them.
  • the communication device according to the invention is preferably designed and set up to send and/or receive data on the basis of any protocol.
  • the data is particularly preferably transmitted wirelessly (e.g.
  • the communication device can be used to transmit data from an external reference source, for example to the electronic control device and/or to the electronic data memory.
  • a particularly preferred embodiment is characterized in that data can be made available to the electronic data memory by means of the communication device and/or by means of a memory unit comprising the active substance container.
  • the data are preferably used to operate the inhaler, ie for example to authenticate the product or the user, start up the inhaler, upload or update the firmware etc. and/or provide information about the active substance to be inhaled by the user, ie for example Information on the type of active substance, the active substance concentration, the carrier medium and the regime.
  • the information contains in particular the active ingredient administration data for administering the active ingredient through the inhaler or already the administration data for operating the inhaler.
  • the data can be standardized and enable the administration element to be controlled in order to enable the inhaler to be used as intended.
  • data in particular the active substance administration data
  • data are made available to the electronic data memory only by means of the communication device and/or by means of a storage unit comprising the active substance containers. This prevents incorrect operation or incorrect provision of active substance administration data.
  • the communication device is designed and set up to communicate with an external source containing the active substance administration data, in order to receive the active substance administration data and/or to send data.
  • the data to be sent are in particular the active ingredient release data recorded by means of the flow rate measuring device.
  • Communication with a delivery source allows drug delivery data to be transmitted directly to the inhaler.
  • the external provision source is used in particular by doctors, hospitals, pharmacies or other qualified persons authorized to dispose of it, in order to preferably establish an encrypted data connection with the communication device of the inhaler.
  • the communication device of the inhaler receives the drug administration data (the code) and stores it in the electronic data store.
  • This provides a safe and reliable means of providing inhaler delivery data from a reliable source.
  • the data, in particular the active substance administration data can preferably only be transmitted to the inhaler via the external source of provision.
  • a prior authentication or authorization of the person entitled to dispose is particularly preferably required (for example via the digital doctor's ID card) in order to send data to the inhaler and/or to receive it from the inhaler.
  • Different user groups of those authorized to dispose of it can have different rights with regard to the availability or modification of the data, for example with regard to the regimen or the active ingredient.
  • a particularly preferred embodiment is characterized in that the external provision source is an application terminal and/or cloud storage and/or a mobile application to receive the drug administration data by means of the communication device and/or to send data.
  • the data to be sent are in particular the active ingredient release data recorded by means of the flow rate measuring device.
  • the external provision source includes or preferably uses means for communication with the communication device of the inhaler, in particular based on Bluetooth, WLAN, ZigBee, NFC, RFID, Wibree, WiMAX, mobile radio, optical etc., particularly preferably an encrypted data connection.
  • the inhaler can be coupled to a mobile application of a communication terminal by means of the communication device in order to send and/or receive data, with the active ingredient administration data being receivable from the cloud memory and/or from the application terminal via the mobile application and can be transferred to the electronic data memory of the inhaler.
  • an expedient embodiment of the invention is characterized in that the inhaler comprises at least one movement sensor in order to detect specific movements of the inhaler before, during and/or after the release of the active substance.
  • the inhaler comprises at least one movement sensor in order to detect specific movements of the inhaler before, during and/or after the release of the active substance.
  • the inhaler further comprises a blocking element, the blocking element in particular blocking the administering element in order to block the delivery of the active substance from the active substance container.
  • the inhaler can comprise a plurality of blocking elements in order to carry out specific blocking of components of the inhaler.
  • the blocking element comprises mechanical means, electronic components or software solutions in order to ensure that the administration element does not administer active substance undesirably.
  • the blocking element blocks, for example, actively the administration element with a A latch, a switch or other physical means, alternatively software control is provided by means of the electronic control device in order to prevent activation of the administration element, as a result of which the active ingredient is not released.
  • a further expedient embodiment of the invention is characterized in that the blocking element can be controlled by means of the electronic control device, with the blocking element blocking the administration element if the electronic control device does not have any active substance administration data. Misuse or incorrect use of the inhaler can be prevented by the blocking element, since manual use of the inhaler is not possible without predefined active substance administration data. This increases safety for the user and increases the verifiability of the therapy or the administration of the active substance.
  • a preferred further development of the invention is characterized in that if the active substance release data at least substantially match the active substance administration data, the electronic control device comprises one or more of the following measures: Outputting a signal to a signaling device comprising the inhaler and/or to the mobile application and /or to the application terminal and/or to the cloud storage; blocking the delivery element with the blocking element; Saving the at least substantially matching of the drug release data with the drug administration data with a location and/or time stamp on the electronic data storage device and/or on the application terminal and/or on the cloud storage device and/or in the mobile application.
  • one or more devices connected to the inhaler to be provided with signals about the inhalation process, in particular that the active substance administered to the user by the inhaler at least essentially corresponds to the active substance to be administered.
  • the electronic control device carries out the respective measures. “At least essentially” within the meaning of the invention means that the active substance release data exactly match the active substance administration data, or there are small deviations between active substance release data and active substance administration data, ie deviations in the range from 1% to 10%. The signal is thus output on the basis of the result of the comparison of the active substance release data recorded by means of the flow measuring device with the active substance administration data.
  • a signal is preferably output after each of the inhalation processes in order to continuously monitor the quality of the inhalation process to inform.
  • the signal can include, for example, an optical, acoustic, electronic and/or mechanical output.
  • the aim of the emitted signal is to inform the user that the inhalation process was successful and that the inhalation process has ended.
  • the signals can, for example, tones, push messages z. B. on a mobile application, LED displays, vibrations, etc., the respective signals on the inhaler and / or to the mobile application and / or to the application terminal and / or to the cloud storage can be transmitted. More preferably, signals can be output when the inhaler is ready for operation and/or when the inhalation process can be carried out.
  • the at least substantial agreement is compared by monitoring and measuring the volume of air inhaled by the user during the inhalation process, ie usually during a puff, using the appropriate sensor system in the inhaler.
  • the measured air volume is compared with the target value of the air volume by the microcontroller, or the amount of active substance contained therein.
  • the electronic control device checks whether the desired drug delivery into the air stream has been successful, i.e. whether the drug delivery data corresponds to the drug delivery data.
  • the measured air volume is compared with the target value of the air volume ("air volume comparison") within a target interval.
  • the electronic control device performs at least one of the following reactions (signals) when the active substance administration data at least substantially match the active substance release data: display of the success of the application to the user, for example by operating a display, green LED, vibration motor, sound, etc.; storing the data relating to the successful use of the inhaler in the data store.
  • a suitable measure can also be to block the inhaler by means of the blocking element. This is useful, for example, when the regimen prescribes some pause between inhalations, which is stored in the drug administration data. After this pause, the blocking element is deactivated again and the user can carry out another inhalation process. This avoids misuse or misuse of the inhaler is stopped.
  • By storing the at least substantially match of the active substance release data with the active substance administration data with a location and/or time stamp it is also ensured that, in particular for those authorized to dispose of it (e.g. doctors), proof can be provided as to when and/or where the active substance was taken taken by the user.
  • a further expedient embodiment of the invention is characterized in that in the event of a defined deviation of the active substance release data from the active substance administration data, the electronic control device comprises one or more of the following measures: outputting a signal to a signaling device comprising the inhaler and/or to the mobile application and/or to the application terminal and/or cloud storage; adjusting the administration data for the delivery of the amount of the active ingredient to be admixed with air flowing in the air passage; blocking the delivery element with the blocking element; receiving new drug administration data via the communication device to generate new administration data; Saving the defined deviation of the drug delivery data from the drug administration data with a location and/or time stamp on the electronic data storage device and/or on the application terminal and/or on the cloud storage device and/or in the mobile application.
  • the inhaler adapts to a user, as it were, in that it takes into account the individual inhalation process of a user when the active substance or liquid is released into the air flow.
  • one or more devices connected to the inhaler to be provided with signals about the inhalation process, in particular that there is a defined deviation of the active substance release data from the active substance administration data, i.e. if the amount of active substance released by the inhaler is not the same as that required by the user absorbed amount of active substance corresponds. It is therefore possible to provide monitoring of the amount of active substance actually released or absorbed, which means that suitable measures can then be initiated if there is a lack of agreement.
  • the aim of the measures taken is to monitor the amount of active ingredient released or taken up, which means that the amount of active ingredient to be released can be adjusted in the next step, so that in future the amount of active ingredient released will at least essentially correspond to the amount of active ingredient taken up by the user, or that the drug delivery data at least substantially correspond to the drug administration data.
  • a signal is preferably emitted after each of the inhalation processes in order to continuously provide data/information about the quality of the inhalation process.
  • the signal can include, for example, an optical, acoustic, electronic and/or mechanical output.
  • the aim of the emitted signal is to inform the patient whether the inhalation process was successful and whether the inhalation process has ended.
  • the signals can, for example, tones, push messages z. B.
  • the respective signals on the inhaler and / or to the mobile application and / or to the application terminal and / or to the cloud storage can be transmitted. More preferably, signals can be output when the inhaler is ready for operation and/or when the inhalation process can be carried out.
  • the comparison of the defined deviation of the active substance release data from the active substance administration data is carried out by monitoring and measuring the volume of air inhaled by the user during the inhalation process, ie usually during a puff, using the appropriate sensor system in the inhaler.
  • the measured air volume is compared with the target value of the air volume by the microcontroller ("air volume comparison") within a target interval or the amount of active substance contained therein.
  • the electronic control device checks whether the desired drug delivery into the air stream has been successful, ie whether the drug delivery data corresponds to the drug delivery data.
  • the active substance release data are calculated on the basis of measured air flow values and are preferably measured air volume flow and/or air mass flow measured values and/or pressure changes in the area of the inhaler through which the air mass flow flows during the inhalation process by the flow measuring device as a function of time.
  • the drug delivery data constitutes a defined, ideal delivery of the drug that is determined by the time course of the air or air-vapor volumetric flow rate (and/or mass flow rate) flowing through the inhaler during at least part or all of the user's ideal inhalation event , is checked.
  • the stored active ingredient release data can be used as a calibration for further inhalation processes of the active ingredient.
  • the electronic control device preferably carries out at least one of the following reactions (signals) when there is a defined deviation between the active substance release data and the active substance administration data: display of the success of the application to the user, for example by operating a display, red LED, vibration motors, sound etc.; storing the data relating to the use of the inhaler in the data store.
  • the inhaler has a fixed active substance administration data profile and the user is trained by appropriate feedback to maintain a suitable air flow, ie inhalation profile, in that deviations are signaled to the user accordingly.
  • a suitable measure includes an adjustment of the activation of the administration element, for example an administration element designed as a heating element (more precisely, the heating current flowing through the heating element and/or the heating duration and/or a pulse-pause ratio of the activation), the adjustment of the vibration speed of a Piezo element or a nebulization membrane or the adjustment of the exit speed of a compressed gas from a nozzle by adjusting a gas pressure, z. B. the air pressure for the amount of liquid to be administered, and / or signaling of a corresponding information for a user on a signaling device.
  • an administration element designed as a heating element more precisely, the heating current flowing through the heating element and/or the heating duration and/or a pulse-pause ratio of the activation
  • B the air pressure for the amount of liquid to be administered, and
  • a preferred option is to signal the user of the inhaler by means of a suitable signaling device that, for example, the amount of active substance released during the inhalation process was not sufficient.
  • the administration can be stopped using the electronic control so that the occurrence of side effects of the medication can be avoided or appropriate measures (e.g. call the emergency doctor or ambulance) can be initiated in an emergency.
  • side effects can preferably also be tracked directly with the help of an app. By looking at the data of many users, an application profile / dosage can be developed, with which side effects can be reduced.
  • the adaptation of the administration data results in a modification of the modalities of administration of the active ingredient, which also results in a changed uptake of the active ingredient by the user.
  • the administration is changed in particular in that the duration of the inhalation process is varied, for example in order to divide the amount of active substance to be administered into two inhalation processes in the future.
  • the process can be dynamic and is dependent on the Drug delivery dates modified. If, for example, the measured value or a value calculated from the measured values deviates from a target value, for example the ratio (total prescribed amount of the active substance composition)/(total amount of air inhaled during the breath), the electronic control device can control the administration element in such a way that that the target value is reached.
  • the electronic control device can switch off the administration element, even if the patient continues to inhale. Once the inhalation process has ended, the electronic control device carries out an action depending on the success of an inhalation process (for example informing the user about successful administration of the active ingredient or the need to repeat an inhalation process).
  • a suitable measure can also be to block the inhaler by means of the blocking element. This is useful, for example, if the determined values appear to require consultation by an authorized person, e.g. B. when the drug release data differs from the drug administration data by more than 50%. However, this can in particular also depend on the active ingredient and/or be stored in the active ingredient administration data.
  • Receiving new drug administration data by means of the communication device for generating new administration data offers the possibility of adapting the drug administration data to the user by the authorized person. This may be required, preferably where the drug release data is clear, i.e. e.g. B. at deviations of more than 50%, deviate from the drug administration data. However, this can in particular also depend on the active ingredient and/or be stored in the active ingredient administration data.
  • the quantity of the released active ingredient is stored in absolute numbers in order to have documentation of the relevant key figures that is as comprehensive as possible available. In this way, the values can be accessed quickly and easily if necessary, which facilitates further measures.
  • the stored data includes, in particular, the unsuccessful use of the inhaler with identification of the failure, the cumulative amount of active ingredient presumably released over the period and the data of a second, subsequent attempt, if applicable.
  • stored data can be transmitted to a mobile electronic device, e.g. B. a smartphone, laptop, smartwatch or tablet PC, are transmitted using the communication device.
  • a mobile electronic device e.g. B. a smartphone, laptop, smartwatch or tablet PC
  • the user himself can monitor the use of the inhaler using the mobile device. He can also set up appointment reminders in the mobile device if the inhaler is to be used at specific times or at recurring intervals.
  • the inhaler More preferably, long-term monitoring of the respective user is possible through the inhaler. It is thus also possible to monitor the frequency of use. An increasing frequency of use can be a sign of getting used to it or that the amount of active substance per inhalation has been set too low. In this way, a dependency/addiction to the active ingredient can also be detected at an early stage.
  • the active substance release data or the active substance administration data can be stored on the electronic data memory and/or a storage unit of the active substance container and/or on the application terminal and/or on the cloud memory and/or in the mobile application or on the communication terminal. In this way, the actual use of the inhaler and application of the active ingredient can be tracked and linked to a physical change of the user.
  • Those authorized to dispose of can more preferably access the data remotely, e.g. B. cloud storage and / or application terminal, at any time check the correct application of the active substance or the active substance administration data.
  • the user can before, during and/or after using the inhaler or the inhalation process, e.g. B. with the help of a mobile application actively and / or passively automatically provide information about his physical condition and physical parameters.
  • data from other devices that have access to physiological data e.g. B. blood pressure, pulse, temperature, oxygen saturation, fitness level, weight, blood sugar, etc., are saved with the data of the last use of the inhaler.
  • a method for administering an active substance with an inhaler comprising a housing with a base body, the main body being designed and set up to accommodate an active substance container containing an active substance, located between at least one air inlet opening and an inhalation opening within the housing extending air channel, an administration element for nebulizing or evaporating the active substance fed from the active substance container to the administration element for admixture to the air flowing in the air channel, an electronic control device, an electronic data memory, and a sensor system with a flow measuring device for measuring the volume and/or or mass flow of the air flowing through the air duct and/or of the active substance flowing through the air duct for storage as active substance delivery data in the electronic data memory, comprising the steps of: providing active substance ff administration data in the electronic data memory of the inhaler, converting the active substance administration data into administration data using the electronic control device of the inhaler, controlling the admixture of the active substance through the administration element to the air flowing in the air duct using the administration data
  • a development of the method is characterized in that the inhaler also includes a communication device in order to send and/or receive data.
  • An expedient embodiment of the invention is characterized in that the electronic data memory is provided with data by means of the communication device and/or by means of a memory unit comprising the active ingredient container.
  • the communication device communicates with an external source containing the active substance administration data, in order to receive the active substance administration data and/or to send data.
  • a further expedient embodiment of the invention is characterized in that the inhaler is coupled to a mobile application of a communication terminal by means of the communication device before data is sent/received for the first time.
  • a further development is characterized in that the active substance administration data is received from the cloud memory and/or from the application terminal and/or via the mobile application using the communication device of the inhaler and is transmitted to the electronic data memory of the inhaler, and in particular by means of the mobile application to the Communication device of the inhaler are sent.
  • the inhaler is used to send data to the mobile application and/or the application terminal and/or the cloud memory.
  • one or more of the following measures are carried out by means of the electronic control device if the active substance release data at least substantially match the active substance administration data: Output of a signal to a signaling device comprising the inhaler and/or to the mobile application and/or to the application terminal and/or to the cloud storage; blocking the delivery element with the blocking element; Saving the at least substantially matching of the drug release data with the drug administration data with a location and/or time stamp on the electronic data storage device and/or on the application terminal and/or on the cloud storage device and/or in the mobile application.
  • a further expedient embodiment of the invention is characterized in that in the event of a defined deviation of the active substance release data from the active substance administration data, one or more of the following measures are carried out by means of the electronic control device: outputting a signal to a signaling device comprising the inhaler and/or to the mobile application and /or to the application terminal and/or to the cloud storage; adjusting the administration data for the delivery of the amount of the active ingredient to be admixed with air flowing in the air passage; blocking the delivery element with the blocking element; receiving new drug administration data via the communication device to generate new administration data; Saving the defined deviation of the drug delivery data from the drug administration data with a location and/or time stamp on the electronic data storage device and/or on the application terminal and/or on the cloud storage device and/or in the mobile application.
  • the method is particularly preferably carried out using an inhaler according to one or more of claims 1 to 11.
  • a new inhaler or active substance container can be ordered automatically if the amount of active substance in the inhaler or in the active substance container falls below a certain level or if a specified limit of a cumulative active substance is exceeded.
  • the inhaler can preferably remind the user to use the inhaler regularly “stand-alone” or, for example, in connection with a mobile application.
  • the inhaler preferably has a real-time clock (RTC) which, after initial synchronization with a clock, for example in a communication terminal, signals devices in the inhaler, e.g. B. LED, display, speaker and / or vibrating device, activated to indicate the recording of the use of the inhaler.
  • RTC real-time clock
  • a time limit for using the inhaler can be specified.
  • the use of the inhaler can be blocked for a specific time, preferably by means of the blocking element. The blocking can occur outside of the specified periods of use of the inhaler.
  • a treatment is carried out in the morning from 7:00 - 9:00, in the afternoon from 12:00 - 14:00, and in the evening from 19:00 - 21:00. Outside of the time, the inhaler cannot be activated and used. Furthermore, the blocking can prevent addiction, whereby for example a maximum number of applications of the inhaler is limited, for example with painkillers.
  • the object is also achieved by an arrangement of the type mentioned at the outset in that the inhaler is designed and set up according to one or more of claims 1 to 11 and the communication terminal and/or the application terminal and/or the cloud memory for sending and/or receiving of data are formed and set up with the inhaler.
  • FIG. 1 shows a schematic view of an inhaler according to the invention in longitudinal section
  • FIG. 2 shows a schematic representation of the inhaler in connection with an external supply source
  • FIG. 6 shows a schematic representation of the use of an arrangement according to the invention.
  • the inhaler shown in the drawing is designed and set up for administering an active substance.
  • the invention relates to comparable products for the administration of active substances with which other substances, for example stimulants or medicinal preparations, are to be administered. From that specifically includes electronic cigarette products and medical inhalers that have a similar structure.
  • the inhaler 10 shown in Figure 1 comprises a housing 11 with a base body 12, wherein the base body 12 is designed and set up to accommodate an active substance container 13 containing an active substance 14, located between at least one air inlet opening 15 and one inhalation opening 16 within the housing 11 extending air duct 17, an administration element 18 for nebulizing or evaporating the active substance 14 fed from the active substance container 13 to the administration element 18 for admixture to the air 23 flowing in the air duct 17, an electronic control device 19, an electronic data memory 20, and a sensor system 21 a flow measuring device 22 for measuring the volume and/or mass flow of the air 23 flowing through the air duct 17 and/or the active substance 14 flowing through the air duct 17 for storage as active substance release data in the electronic data memory 20.
  • the inhaler preferably comprises 10 at least one energy source 27, for example for supplying the electronic control device 19 and the administering element 18 and the other electrical or electronic components with energy.
  • This inhaler 10 is characterized according to the invention in that the electronic control device 19 of the inhaler 10 is designed and set up to convert active substance administration data provided in the electronic data memory 20 for the administration of the active substance 14 through the inhaler 10 into administration data in order to enable the admixture of the active substance 14 through the Administering element 18 to control air 23 flowing in the air duct 17, and wherein the electronic control device 19 is set up to calculate the active substance 14 released from the active substance container 13 using the active substance release data recorded by the flow measuring device 22 and to compare it with the active substance administration data.
  • the air 23 flowing in the air duct 17 is shown stylized in FIG. 1, the air 23 flowing in the air duct 17 generally not being visible, or the flowing air 23 being regularly in the form of vapor or aerosol, for example.
  • the air 23 flowing in the air duct 17 comprises when the inhaler 10 is used, i.e. during the inhalation process, provided the user is at the inhalation opening 16 sucks, the active substance 14.
  • the active substance 14 is transported through the air 23 flowing in the air duct 17.
  • the housing 11 of the inhaler 10 can in principle have any color and shape and is not restricted in terms of design or the choice of material.
  • the housing 11 is structured in such a way that it includes an area for accommodating and/or enclosing the active ingredient container 13 within the housing 11 of the inhaler 10 .
  • the inhaler 10 shown in FIG. 1 corresponds to the schematic structure of a medical inhaler, although a more elongated structure, comparable to that of an electronic cigarette, is also conceivable, for example. It is irrelevant for the inhaler 10 according to the invention whether the inhaler 10 or parts thereof are designed as disposable or reusable items.
  • the active ingredient container 13 can preferably be designed as a disposable item and have an additional electronic data memory/memory unit—not shown in the figures—on which, for example, active ingredient administration data and/or administration data for controlling the inhaler 10 are stored.
  • the active substance 14 that is located in the active substance container 13 and is to be administered is preferably dissolved in a liquid and is present as a mixture.
  • the active ingredient 14 in the active ingredient container 13 can be present as a gas, or be a compressed liquid or be dissolved in a compressed liquid.
  • the mixture includes, for example, one or more of the following components: 1, 2-propylene glycol, glycerol, water, at least one aroma and one or more active ingredients 14.
  • the composition of the liquid depends on the active substance 14 to be administered and can be designed according to the pharmacological requirements.
  • the inhaler 10 shown schematically serves the purpose of administering the active substance 14 via the inhalation opening 16 to the respective user of the inhaler 10 - not shown in the drawings administered to the air channel 17 flowing air 23, whereby this air 23 is in turn taken orally by the user.
  • the administering element 18 can be designed as required, the active substance 14 being administered from the active substance container 13 in each case.
  • the administering element 18 is controlled by means of the electronic control device 19, to deliver the agent 14 according to the provided agent delivery data.
  • the active substance administration data are provided in the electronic data memory 20 and can be converted into administration data by means of the electronic control device 19 .
  • the administration data form the data for administering the active ingredient 14 by means of the administering element 18, which is controlled by the electronic control device 19.
  • the active substance 14 in vapor or aerosol form generated by the administration element 18 escapes from the administration element 18 and is mixed with the air 23 flowing in the air duct 17, see Fig. 1.
  • the flow measuring device 22 determines the quantity of the administered by the sensor system 21 Active substance 14 and calculates the active substance release data by means of the electronic control device 19 in order to compare them with the active substance administration data.
  • the electronic data memory 20 is advantageously non-volatile and is used, for example, to store the active substance administration data, the administration data, the active substance release data, the data of the sensor system and other general information or parameters about the operation of the inhaler 10.
  • the data memory 20 can be part of the electronic control device 19.
  • the data memory 20 advantageously contains information on the composition of the liquid or the active substance 14 stored in the active substance container 13, information on the functioning of the administration element 18, in particular for power/temperature control etc., data for status monitoring or system testing, for example leak testing, data relating to Protection against copying and counterfeiting, an ID for unique identification, serial number, date of manufacture, expiry date, number of inhalations and/or time of use are stored.
  • the sensor system 21 has a flow measuring device 22, which is embodied here as a differential pressure measuring device.
  • the flow measuring device 22 has a first pressure sensor—not shown in detail in the figures—which is arranged in such a way that it is set up to measure the atmospheric air pressure outside the housing 11 of the inhaler 10 .
  • a measuring opening can be provided in the housing 11 in order to fluidly connect the first pressure sensor to the atmosphere.
  • the flow rate measuring device 22 also has a second pressure sensor—not shown in detail in the figures—which is arranged in such a way that it is set up to measure the air pressure prevailing in the air duct 17 .
  • the electronic control device 19 can, through knowledge of the Cross-section of the air duct 17 at the measuring point of the second pressure sensor and the pressure difference measured between the first and second pressure sensor calculate the air volume flow through the inhaler 10 and determine the air volume flow over time by repeated measurement.
  • the sensor system 21 can have a vapor quantity sensor for detecting the quantity of active substance, liquid or vapor administered by the administration element 18 during an inhalation device.
  • the amount of steam sensor can, for example, be an air humidity sensor (not shown in detail).
  • the inhaler 10 preferably comprises a communication device 24, designed and set up to send and/or receive data.
  • Data can preferably be made available to the electronic data memory 20 by means of the communication device 24 and/or by means of a memory unit—not shown in the figures—which comprises the active substance container 13 .
  • the data are in particular the data for operating the inhaler 10 or for administering the active ingredient 14 and/or data that are determined during the inhalation process.
  • the communication device 24 is designed and set up to communicate with an external supply source 25 containing the active substance administration data (see FIG. 2) in order to receive the active substance administration data and/or to send data.
  • the sending and receiving of data is indicated in FIG. 2 by the double arrow between the inhaler 10 and the supply source 25 .
  • the inhaler 10 and the supply source 25 are shown schematically in a simplified manner, the possibility of communicating with one another being apparent from FIG. 2 .
  • the communication device 24 of the inhaler 10 preferably includes means for the wireless transmission of data z. B. on the basis of Bluetooth, WLAN, ZigBee, NFC, RFID, Wibree, WiMAX, mobile radio, optical, alternatively, wired data transmission or communication is also possible.
  • the external supply source 25 preferably also includes at least one of the aforementioned means or communication options in order to form and set up a connection or communication with the inhaler 10 .
  • the external provision source 25 (see FIG. 2) preferably includes an application terminal and/or a cloud storage device and/or a mobile application—not shown in the figures—in order to receive the active substance administration data by means of the communication onthe device 24 to receive and/or to transmit data.
  • the external supply source 25 is selected depending on the intended use or configuration of the inhaler 10, the active substance 14 to be administered or the person entitled to dispose of it.
  • the inhaler 10 can advantageously be coupled by means of the communication device 24 to a mobile application of a communication terminal device--shown schematically as an external supply source 25 in FIG can be received by the application terminal via the mobile application and can be transmitted to the electronic data memory 20 of the inhaler 10.
  • the transmission of the data is shown schematically in FIG. 2 as a double arrow.
  • the external provisioning source 25 may be divided into several separate components that perform different sub-functions of the overall functionality of the external provisioning source 25 .
  • the mobile application can be used, for example, to display additional information or to output signals while data is provided in the cloud storage device in order to retrieve it using the communication terminal.
  • the inhaler 10 comprises at least one movement sensor 26 in order to detect specific movements of the inhaler 10 before, during and/or after the release of the active ingredient.
  • the motion sensor 26 may be a separate component, or the motion sensor 26 may be integrated into the electronic control device 19, for example.
  • the inhaler 10 preferably further comprises a blocking element 28, the blocking element 28 blocking in particular the administering element 18 in order to block the delivery of the active substance 14 from the active substance container 13.
  • the blocking element 28 is designed as an object, but electronic control components are alternatively also conceivable which block the administration of the active substance 14 from the active substance container 13 by the administration element 18 . It is also possible for the blocking element 28 to be arranged directly at the outlet opening of the active substance container 13 in order to block administration of the active substance 14 .
  • the blocking element 28 is preferably controllable by means of the electronic control device 19, the blocking element 28 blocking the administration element 18 if the electronic control device 19 has no drug administration data.
  • the inhaler 10 preferably comprises a signal device 29.
  • the signal device 29 comprises, for example, optical, acoustic and/or haptic signal elements, for example one or more LEDs, a digital display, a display, a haptic signal generator and/or an acoustic signal generator.
  • the method is described for administering an active substance 14 with an inhaler 10 .
  • the method includes steps S1 to S5.
  • active ingredient administration data is provided in an electronic data memory 20 of the inhaler 10.
  • the data can be made available to the electronic data memory 20 in a wide variety of ways.
  • the active substance administration data are provided, for example, via a memory unit of the active substance container 13 or can be received by means of a communication device 24 .
  • step S2 the active ingredient administration data is converted into administration data by means of an electronic control device 19 of the inhaler 10 .
  • the administration of the active substance 14 via an administration element 18 can be controlled by means of the administration data.
  • the delivery data is based on the drug delivery data and converts the data into control signals in order to adapt the drug delivery data to a respective delivery element 18 .
  • step S3 the admixture of the active substance 14 by the administering element 18 to air 23 flowing in an air duct 17 is controlled by means of the administering data.
  • the inhaler 10 is controlled by the administration data as a function of its comprehensive components, so that the active substance 14 to be administered corresponds to the active substance administration data.
  • the active substance 14 released from the active substance container 13 is calculated using the active substance release data recorded by means of a flow measuring device 22 of the inhaler 10.
  • the air components of the air 23 flowing through the air duct 17 during the active substance removal would be calculated and the amount of active substance 14 actually administered can be determined and stored in the active substance delivery data.
  • the active substance delivery data thus represent the active substance 14 actually delivered, which was ingested by the user of the inhaler 10 during the performance of the previous steps S1 to S3.
  • step S5 the drug administration data is compared with the drug release data.
  • a successful inhalation event is when the drug release data matches the drug administration data.
  • the electronic control device 19 is used to calculate how the inhalation process proceeded as a function of the active substance administration data with the active substance release data. The comparison can be based on both absolute data and relative data.
  • the data provided and/or generated during the implementation of steps S1 to S5 can be transmitted to an external source of supply 25 by means of a communication device 24 of the inhaler 10, with the external source of supply 25 comprising in particular a mobile application, an application terminal and/or cloud storage.
  • step SE1 the output of a signal to a signaling device 29 comprising the inhaler 10 and/or to the mobile application and/or to the application terminal and/or to the cloud memory.
  • the signal is issued after the inhalation process is complete and after the comparison of the drug administration data with the drug delivery data has been completed.
  • the signal informs the user of the inhaler 10 that the inhalation process has been carried out successfully, ie that the active substance administration data match the active substance release data.
  • the signal is preferably presented optically, haptically and/or acoustically by means of a signaling device 29 . Further measures relating to the inhaler 10 can be carried out by means of the electronic control device 19 as a result of the signal.
  • step SE2 for example, the blocking takes place subsequently or as an alternative to SE1 of the administering element 18 or the inhaler 10 through the blocking element 28. This step is preferably designed to be reversible.
  • step SE3 the at least substantially matching active substance release data are stored with the active substance administration data with a location and/or time stamp on the electronic data storage device 20 and/or on the application terminal and/or on the cloud storage device and/or or stored in the mobile application.
  • step S5 the comparison carried out in step S5 by means of the electronic control device 19 leads to a defined deviation of the active substance release data from the active substance administration data
  • step SU1 the output of a signal to a signaling device 29 comprising the inhaler 10 and/or to the mobile application and/or to the application terminal and/or to the cloud memory.
  • the signal is issued after the inhalation process is complete and after the comparison of the drug administration data with the drug delivery data has been completed.
  • the signal informs the user of the inhaler 10 of the unsuccessful performance of the inhalation process, i.e. of the deviation of the drug delivery data from the drug administration data.
  • the signal can be used to carry out further measures relating to the inhaler 10 by means of the electronic control device 19, in which case the signal is in particular a control signal.
  • step SU1 the administration data for the delivery of the quantity of active substance 14 for admixture to the air 23 flowing in the air duct 17 is adjusted in SU1.
  • the administration data are based on the comparison made in step S5 between the active substance administration data and the active substance delivery data performed.
  • the administration data are adapted in particular such that delivery of the active substance 14 to air 23 flowing in the air duct 17 is changed by means of the administration element 18 .
  • the administration data can be adapted, for example, such that the duration of the delivery of the active substance 14 to the air 23 flowing in the air duct 17 is varied by means of the administration element 18; for example, that the amount of active substance 14 to be taken up in one inhalation process is divided into two inhalation processes in order to administer the active substance 14 completely gain.
  • the administration data is thus adjusted, but the drug administration data is retained.
  • the drug 14 delivered to the user by the inhaler 10 is again compared to one another.
  • step SU3 subsequently or as an alternative to steps SU1 and/or SU2, the administering element 18 or the inhaler 10 is blocked by the blocking element 28.
  • This step is preferably designed to be reversible.
  • step SU4 new active substance administration data are received from the inhaler 10 by means of the communication device 24 for generating new administration data.
  • the new drug delivery data preferably includes a changed prescription for drug 14 delivery.
  • steps SU2 and/or SU4 are preferably repeated as often as desired until the active substance release data at least substantially match the active substance administration data in the further inhalation processes that are carried out.
  • step SU5 the defined deviations of the drug delivery data from the drug administration data are recorded with a location and/or time stamp on the electronic data storage device 20 and/or on the application terminal and/or on the cloud storage device and/or stored in the mobile application. This process is preferably repeated any number of times until there is at least a substantial agreement between the active substance release data and the active substance administration data.
  • Steps SE1 and/or SE2 or steps SU3 and/or SU5 take place if the active substance release data at least substantially match the active substance administration data after the inhalation process has been carried out again with changed active substance administration data.
  • FIG. 6 shows the inhaler 10 preferably as part of an arrangement 30 which is designed and set up for administering an active substance 14 .
  • the arrangement 30 comprises an inhaler 10 and a communication terminal 32 comprising a mobile application 31 and/or an application terminal and/or a cloud memory 33, wherein the inhaler 10 is designed and set up according to one or more of claims 1 to 11 and the communication terminal and/or the application terminal and/or the cloud storage device are designed and set up to send and/or receive data with the inhaler 10.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Anesthesiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

La présente invention concerne un inhalateur (10), comprenant : un boîtier (11) présentant un corps principal (12), le corps principal (12) étant conçu et configuré pour recevoir un récipient à principe actif (13) contenant un principe actif (14) ; un canal à air (17) s'étendant à l'intérieur du boîtier (11) ; un élément d'administration (18) pour mélanger le principe actif avec de l'air (23) s'écoulant dans le canal à air (17) ; un dispositif de commande électronique (19) ; une mémoire de données électroniques (20) ; et un système capteur (21) présentant un dispositif de mesure d'écoulement (22) pour mesurer l'écoulement volumique et/ou massique de l'air (23) s'écoulant à travers le canal à air (17) et/ou le principe actif (14) s'écoulant à travers le canal à air (17) pour le stockage en tant que données de distribution de principe actif dans la mémoire de données électroniques (20). Le dispositif de commande électronique (19) est conçu et configuré pour convertir des données de distribution de principe actif en données d'administration afin de commander le mélange, par l'élément d'administration (18), du principe actif (14) avec de l'air (23) s'écoulant dans le canal à air (17) et le dispositif de commande électronique (19) étant configuré pour calculer le principe actif (14) distribué à partir du récipient à principe actif (13) sur la base des données de distribution de principe actif capturées au moyen du dispositif de mesure d'écoulement (22) et pour le comparer aux données d'administration de principe actif. L'invention concerne également un procédé et un agencement correspondants.
EP21769926.3A 2020-08-31 2021-08-25 Inhalateur et procédé et agencement d'administration d'un principe actif Pending EP4204049A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102020122651.9A DE102020122651A1 (de) 2020-08-31 2020-08-31 Inhalator sowie Verfahren und Anordnung zum Verabreichen eines Wirkstoffs
PCT/EP2021/073512 WO2022043380A1 (fr) 2020-08-31 2021-08-25 Inhalateur et procédé et agencement d'administration d'un principe actif

Publications (1)

Publication Number Publication Date
EP4204049A1 true EP4204049A1 (fr) 2023-07-05

Family

ID=77750253

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21769926.3A Pending EP4204049A1 (fr) 2020-08-31 2021-08-25 Inhalateur et procédé et agencement d'administration d'un principe actif

Country Status (5)

Country Link
US (1) US20230310764A1 (fr)
EP (1) EP4204049A1 (fr)
CN (1) CN115989408A (fr)
DE (1) DE102020122651A1 (fr)
WO (1) WO2022043380A1 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284133A (en) * 1992-07-23 1994-02-08 Armstrong Pharmaceuticals, Inc. Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means
CA3046359A1 (fr) * 2016-12-09 2018-06-14 Microdose Therapeutx, Inc. Inhalateur
CA3056897A1 (fr) * 2017-03-22 2018-09-27 Microdose Therapeutx, Inc. Capteur optique de dose d'inhalateur de poudre seche
WO2019157208A1 (fr) * 2018-02-08 2019-08-15 Optimist Inhaler LLC Éléments de sécurité pour inhalateur doseur électronique
WO2019239217A1 (fr) * 2018-06-14 2019-12-19 Nexvap Sa Appareil électromécanique et procédé d'utilisation d'un inhalateur mobile
US11090449B2 (en) 2018-08-21 2021-08-17 Vivera Pharmaceuticals Inc. Smart inhaler device with automated dose delivery, measurement, and management

Also Published As

Publication number Publication date
CN115989408A (zh) 2023-04-18
US20230310764A1 (en) 2023-10-05
WO2022043380A1 (fr) 2022-03-03
DE102020122651A1 (de) 2022-03-03

Similar Documents

Publication Publication Date Title
DE69530845T2 (de) Gerät zur intrapulmonaren Arzneiverabreichung in therapeutisch relevanten Einatmungsfluss/Volumenwerten
US20220246263A1 (en) Nebulizing devices and systems having biometric data acquisition and monitoring capabilities
DE69433380T2 (de) Systeme zur interpulmonaren verabreichung von wässrigen lösungen
US20220262507A1 (en) Pharmaceutical and biological agent delivery system having biometric data acquisition and monitoring capabilities
DE69534450T2 (de) Vorrichtung zur vernebelung von betäubungsmitteln
DE69225604T2 (de) Inhalator mit feedback für den patienten sowie für medizinisches personal
EP3399972B1 (fr) Traitement thérapeutique à faible dose
DE69937558T2 (de) Gerät zur linderung von schmerz bei bewusstsein und angstzuständen im zusammenhang mit medizinischen und chirurgischen eingriffen
EP1258264B1 (fr) Appareil pour l'administration d'aérosol
DE60030457T2 (de) Arzneimittel-verabreichungssystem
JP4377226B2 (ja) 適切な臨床的発見法に従って意識のある患者の医療または手術手法に伴う苦痛または不安を緩和するためのシステム
CN1622839B (zh) 病人监测系统和护理系统
DE69832183T2 (de) Vorrichtung zum verabreichen von insulin in kontrollierten doserungen durch kontrolle des totalen inhalierten volumens
WO2006048417A1 (fr) Systeme et appareil de suivi de l'observance d'une therapie respiratoire
WO2016064786A1 (fr) Dispositif d'administration de formes galéniques d'agent pharmaceutique solide et d'acquisition de données biométriques
US11344686B2 (en) Method of respiratory system treatment
EP2651479A1 (fr) Appareil de thérapie
CN114728123A (zh) 被配置成确定药物给药方案的药物施用系统
EP4204049A1 (fr) Inhalateur et procédé et agencement d'administration d'un principe actif
WO2005123165A1 (fr) Appareil d'assistance a l'inhalation et methode d'assistance pour des therapies d'inhalation
DE19939417C2 (de) Vorrichtung zur Applikation von Medikamenten durch Inhalieren und Verfahren zur Steuerung einer Inhalationsvorrichtung
DE102020110258B4 (de) Inhalator
US20210170122A1 (en) Method of weight regulation using nebulized nicotine
WO2022020855A1 (fr) Méthode de traitement de système respiratoire
EP4370181A1 (fr) Systèmes, dispositifs et procédés d'administration de médicament

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230324

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)